Amphastar Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|
| Revenue | $240.2M | $255.2M | $251.5M | $210.5M | $229.7M | $204.3M |
| Cost of Revenue | $149.7M | $151.0M | $174.2M | $159.2M | $142.7M | $114.0M |
| Gross Profit | $90.5M | $104.2M | $77.3M | $51.3M | $87.0M | $90.3M |
| Gross Margin | 37.7% | 40.8% | 30.8% | 24.4% | 37.9% | 44.2% |
| Operating Expenses | ||||||
| Research & Development | $43.5M | $41.5M | $37.3M | $28.9M | $33.0M | $31.2M |
| SG&A Expense | $44.5M | $41.8M | $41.5M | $34.8M | $31.0M | $27.2M |
| Operating Income | $-1.3M | $15.4M | $-6.9M | $-18.0M | $17.5M | $25.4M |
| Operating Margin | -0.5% | 6.0% | -2.7% | -8.5% | 7.6% | 12.4% |
| Interest Expense | $826.0K | $1.0M | $987.0K | $609.0K | $958.0K | $784.0K |
| Pretax Income | $1.2M | $14.6M | $-10.4M | $-18.1M | $17.2M | $25.9M |
| Income Tax Expense | $-2.4M | $4.8M | $-7.6M | $-7.4M | $5.4M | $7.8M |
| Net Income | $3.6M | $9.8M | $-2.8M | $-10.7M | $11.9M | $18.1M |
| Net Margin | 1.5% | 3.8% | -1.1% | -5.1% | 5.2% | 8.9% |
| EPS (Basic) | $0.08 | $0.22 | $-0.06 | $-0.25 | $0.31 | $0.47 |
| EPS (Diluted) | $0.08 | $0.21 | $-0.06 | $-0.25 | $0.31 | $0.46 |
| Shares Outstanding (Basic) | 46.1M | 45.4M | 45.0M | 42.0M | 38.7M | 38.6M |
| Shares Outstanding (Diluted) | 48.4M | 47.5M | 45.0M | 42.0M | 38.9M | 38.9M |
| Dividends Per Share | — | — | — | — | — | — |